IMGENE will establish novel tools and protocols for improved CRISPR genome editing efficiency that will be of immediate benefit for health and life science research, the pharmaceutical industry, and the application of gene therapy. In addition, IMGENE addresses crucial ethical questions related to the application of genome editing technology in animals, plants, and humans, which have to be solved to gain acceptance by the society. By excellent research training of 8 ESRs on a scientifically and economically highly relevant topic and additional training in transferable skills, IMGENE will educate novel leaders with great career perspectives in industry and academia.
We are a group of 6 academic and 1 industrial beneficiary, 2 industrial partners and 1 Patient organization.
IMGENE is funded by the Marie Curie initiatives of the European Commission. The network will start September 1st, 2017 and be active for three years.